1Ajay K Kakkar, Robin C N, Williamson M A. Prevetion of venous thromboembolism in Cancer. Patients Seminars In Thrombosis And Hemosatsis, 1999,25(2):381.
2Steven R, Deitcher, Marceb P V, et al. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma.Cancer ,2004, 101(3): 439.
3AgnesY.Y.YLee. Epidemiology and management of venous thromboem bolism in patients with cancer thrombosis. Research, 2003,110:167.
4Ajay K Kakar, Mark Levine, H M Pinedo, et al. Venous thrombosis in cancer patients: insights from the frontline survey. The oncologist,2003,8:381.
5Graham J Caine, Paul S stonelake, Daniel Rea, et al. Coagulpochic complications in breast cancer. Cancer, 2003,98(8) 1578.
6R.Scott Braithwaite, Rowan T Chlebowski, Joseph Lau, et al.Meta-analysis of vascular and neoplastic events associated with tamoxifen. Journal of general internal medicine, 2003,18:937.
7Frederick R. Rickles, Anna Falanga. Molecular basis for the relationship between thrombosis and cancer. Thrombosis Research,2001,102:215.
8I C Cameron , I A F Azmy. Thrombopmphylaxis in patients undergoing surgery for breast cancer. The Breast,2001,10:535.
1Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta - analysis comparing low - molecular - weight heparins with unfractionated heparin in the treatment of venous tromboembolism: examining some unanswered questions regarding location of treatment, product
2Faivre R, Neuhart Y, Kieffer Y, et al. A new treatment of deep venous thrombosis: low molecular weight heparin fractions. Presse Med,1988, 17: 197-200.
3Yeager BF, Matheny SC. Low - molecular- weight heparin in outpatient treatment of DVT. Am Farm Physician, 1999, 59:945 -952.
4Grole JB. Treatment of deep vein thrombosis using low - molecularweight heparins. Am J Manage Care, 2001, 7 (17 suppl): 515-523.
